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A 6 year. experience of cardiac valve replacement with
the Omniscience prosthesis is described. A total of 253
valves were inserted in 219 patients. The survivors were
followed up for a total of 536 patient-years and for a
mean of 2.8 years. The follow-up was 97.6% complete.
Analyses .Were performed in accordance with recom-
mended criteria regarding definitions of complications
and grading thromboembolic events for severity and
analysis of anticoagulant status. Results are described
both in terms of actuarial and linearized rates.
For the patients at risk, actuarial survival at the end
of 5 years was 87.9 ± 3.1 % overall, 90.4 ± 3.0% for
single valve (aortic 88 ± 5%, mitral 93.3 ± 4%) re-
placement and 71 ± 11% for multiple valve replace-
The ideal valvular prosthesis has yet to be designed and
consequently work is continuing to improve on the available
substitutes. The Omniscience cardiac valve, which is de-
rived from and superior to its predecessor, the Lillehei-
Kaster valve, is a good example. Housed in a one piece
titanium frame, it is a low profile central flow valve that
has a free floating concave-convex pivoting occular disc
made of pyroIitic carbon. We found these features attractive
and. began implanting these valves in 1979. The first Ca-
nadian Omniscience valve implantation was performed in
Edmonton. To this date the 73 year old recipient is doing
well.
Data on the Omniscience valve (1-3) are scarce because
in the United States only primary investigative centers had
been to obtain the valve before it was given full approval
by the Food and Drug Administration in May 1985. There
have also been some published data generated outside the
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ment. The actuarial rates offreedom from complications
were as follows: endocarditis 95.7 ± 1.8% (aortic 94 ±
3.5%, mitral 100%), periprosthetic leak 98 ± 1% (aor-
tic 96.2 ± 2.6%, mitral 100%), thromboembolism
95.2 ± 2.3% (aortic 90.9 ± 4.6%, mitral 96.7 ± 3.3%),
valve thrombosis 98.7 ± 0.9% (aortic 100%, mitral
100%), anticoagulant-induced bleeding 90.3 ± 2.6%
and all valve-related complications 79.4 ± 3.6% (aortic
78.8 ± 3.6%, mitral 85.9 ± 4.5%). The functional
improvement in patients was very satisfactory and the
risk of reoperation was 1.1% per patient-year. Over a
6 year time frame, the Omniscience valve has given ex-
cellent clinical performance.
(J Am Coil Cardiol1987;9:240-6)
United States. Therefore, stimulated by the few reports of
poor results in England and in Spain, we decided to analyze
our experience in a retrospective study based on the pooled
data from two Canadian centers.
Methods
Patients. Data from all patients receiving the Omnis-
cience valve were compiled between November 1979 and
June 1985 in two Canadian centers: The University of Al-
berta Hospital in Edmonton (194 patients) and the Victoria
Hospital in London, Ontario (25 patients). These centers
have a wide referral base and many patients go back to
outlying areas that are without immediate access to specialist
centers.
A total of 253 Omniscience valves were inserted in 219
patients: 190 received a single valve replacement, 26 double
and 3 triple. The follow-up of current patients was done
through office visits, telephone contact with the patients and
their doctors and study of the hospitals' and the referring
doctors' charts. All information was recorded at the Uni-
versity of Alberta Hospital and processed for actuarial anal-
ysis and linearized rates for complications using an IBM
PCXT computer and Revelation System.
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Follow-up. Current follow-up was obtained for 192 pa-
tients at risk (97.6%); only 2 patients were unavailable for
follow-up. Three patients (1.5%) were removed from the
study; t'Y0 of these underwent Omniscience valve expla-
nation and subsequently received a biologic prosthesis be-
cause of valve thrombosis in one and valve obstruction due
to pannus formation in the other; the third patient was re-
moved from the study for an undetermined reason. The
patients at risk were followed up for a total of 536.4 patient-
years with a mean follow-up time of 2.8 years and (maxi-
mum 6).
Operative techniques. Valve replacement was carried
out using cold cardioplegia and standard techniques; par-
ticular attention was paid to anular preparation, valve sizing
and orientation. Interrupted Teflon buttressed mattress su-
tures were routinely used in valve insertion.
Anticoagulation. Anticoagulant therapy began when the
patient was able to tolerate oral fluids, usually on the second
or third day. When discharged the patients were advised to
nave their physician maintain their prothrombin times at 2
to 2 112 times normal. One hundred eighty patients (92.8%)
were receiving warfarin alone, two (1%) were receiving
warfarin and dipyridamole (dipyridamole was added after
the occurrence of a transient ischemic attack) and three
(1.5%) were receiving aspirin alone (pediatric age group).
Two patients (1%) were not taking any anticoagulant. An-
ticoagulant status could not be determined in seven patients
(3.6%), including two patients (1%) who were lost to fol-
low-up.
Patient profile. The mean age for the whole group was
50.2 ± 14.5 years; (range 2 months to 75 years) (Table 1).
The distribution of patients according to implant site and
sex is shown in Table 2. There was a preponderance of
rheumatic valvular disease as an indication for surgery (68.9%)
(Table 3). Previous prosthetic valve malfunction in other
prostheses (10%) and endocarditis (9.1 %) were major in-
dications. A large number of patients had previous cardiac
surgery (Table 4). Concomitant major operative procedures
were commonly performed (Table 5).
Valve size bears an important relation to the valve-
related complication. In our series the mean anular tissue
Table 1. Distribution of 219 Patients By Age
Age Group
Patients
(yr) No. %
o to 10 3 1.4
II to 20 5 23
21 to 30 14 6.4
31 to 40 27 12.3
41 to 50 42 19.2
51 to 60 78 35.6
61 to 70 44 20.1
71 to 80 6 2.7
Table 2. Distribution of 219 Patients According to Implant Site
and Sex
No. of Patients
Implant Site Male Female Total % of Total
AVR 60 16 76 34.7
MVR 41 61 102 46.6
TVR 3 9 12 5.5
Multiple 8 21 29 13.2
Total 112 107 219 100
AVR = aortic valve replacement; MVR = mitral valve replacement;
TVR = tricuspid valve replacement.
diameter for the aortic valve was 24.0 ± 2.5 mm, and for
the mitral valve 27.6 ± 2.1 mm.
Results
Mortality. The 30 day hospital mortality for the whole
group, irrespective of cause of death, was 11.4% (25 of 219
patients). Mortality breakdown according to implant site is
as follows: aortic valve 11.8% (9 of 76); mitral valve 11.7%
(12 of 102); tricuspid valve 8.3% (1 of 12); single valve
replacement 11.6% (22 of 190) and multiple valve replace-
ment 10.3% (3 of 29 patients). There were 17 late deaths
(7.7%); 5 in the aortic valve group (6.5%) and 5 in the
mitral valve group (4.9%). .
Survival data. For the patients at risk (survivors), ac-
tuarial survival at the end of 5 years was 87.9 ± 3. 1 for
the whole group (aortic valve 88.2 ± 5.1, mitral valve
93.3 ± 3.7) (Fig. 1). As expected, the patient's preoperative
New York Heart Association functional classification and
age at surgery had a tremendous impact on outcome. Five
year survival in patients in .preoperative functional
classes II, III and IV was 97.6 ± 22.4%,89.3 ± 4.4% and
80.2 ± 6.3%, respectively. Similarly, 5 year survival. in
patient age groups 0 to 40, 41 to 50, 51 to 60 and 61 to 80
years was 97.2 ± 2.8%,92.3 ± 7.4%,84.9 ± 5.3% and
81. 2 ± 7.3%, respectively. A gratifying improvement in
the patients' postoperative status occurred (Fig. 2).
Complications
These are considered in patients at risk; stringent criteria
were used to define complications.
Endocarditis (Fig. 3). Infective endocarditis occurred
in seven patients at an annual rate of 1.3% per patient-year;
this includes all episodes, including those in patients in
whom endocarditis occurred on a native valve or those who
previously had prosthetic valve endocarditis. Four cases
occurred after aortic valve replacement and two each after
tricuspid valve and combined aortic and mitral valve re-
placement. In three patients, endocarditis occurred as a com-
plication of surgery: one tricuspid, one aortic and one triple
valve replacement. The remaining four patients had endo-
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Table 3. Cause of Valvular Disease in 219 Patients Undergoing 253 Valve Replacements
AVR MVR TVR Mull. Total*
Rheumatic 30 87 7 27 151 (6ll9)
Congenital II 4 4 19 (ll.7)
Calcific aortic valve disease 30 30 (13.7)
Endocarditis 9 6 5 20 (91)
Previous prosthetic valve malfunction 3 12 3 4 22 (10)
Other! 3 16 1 3 23 (105)
*figures in parentheses indicate percentages: some patients have multiple causes: tlncludes ischemic and
degenerative causes: Mult. = multiple valve replacement Other abbreviations as in Table 2
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carditis before the insertion of the Omniscience valve. Two
of these died (0.34% per patient-year). Three patients were
treated medically and the remainder came to surgery. One
patient who had preoperative endocarditis died 9 days post-
operatively: because this was an early death. he has been
excluded from the analysis.
Peri prosthetic leak (Fig. 4). This complication. ex-
cluding those due to active endocarditis, occurred in three
patients (0.6 per patient-year): two in the aortic position and
one in the mitral. One patient had aortic valve replacement
for aortic regurgitationand 16months later a leakdeveloped.
The second patient had previous mitral valve replacement
with another mechanical prosthesis; the Omniscience valve
was implanted because of prosthetic endocarditis. He de-
veloped a periprosthetic leak and came to surgery I year
later. Both of these patients were treated by simple resu-
turing of the prosthesis to the valve anulus.
The third patient was a 70 year old man with previous
native aortic valve endocarditis. At the original operation
he had required aortic valve replacement. open mitral com-
missurotomy. coronary artery bypass grafting and circula-
tory assistance with the intraaortic balloon pump. Six months
later he died. and autopsy showed periprosthetic valve de-
hiscence (fatal periprosthetic leak 0.2% per patient-year).
Thromboembolism (Table 6, Fig. 5). Thromboembolic
episodes during active endocarditis are excluded. Eighteen
of the 194patients at risk hadepisodes of thromboembolism.
Of these. II patients had transient ischemic attacks only (2
after aortic, 6 after mitral, and I after tricuspid valve re-
placement and 2 after multiple valve replacement). These
patients were advised to exercise a tight prothrombin time
control of their warfarin dosage and some were also pre-
scribed dipyridamole. Five patients had an embolic deficit
(0.9% per patient-year). four after aortic and one after mitral
valve replacement.
Valve thrombosis (Fig. 6). This occurred in three pa-
tients (0.6% per patient-year). one of whom died (fatal valve
thrombosis 0.2% per patient-year) 7 months after a triple
valve replacement. This patient died before surgery and the
thrombosedvalve wasconfirmedon autopsy. Of the nonfatal
valve thromboses. one occurred in a 27 year old woman
who at age 21 had had tricuspid valve replacement with a
Beall prosthesis. Six years later it malfunctioned when she
became pregnant and stopped taking warfarin. At the time
of delivery she presented in extremis and required emer-
gency tricuspid valve replacement with the Omniscience
valve. One year later she again presented with a malfunc-
tioning prosthesis and her Omniscience 31 valve was re-
placed with a smaller size and excellent results. The other
patient was a 47 year old man who had a valve thrombosis
51/2 years after mitral valve replacement, which was then
replaced with a biologic prosthesis. At the time of the first
operation, it was noticed that he had a giant left atrium with
thrombus in it. Both of these patients are doing well. In the
event free curve for valve thrombosis (Fig. 6) it should be
noted that one patient had a valve thrombosis 51J2 years after
mitral valve replacement. Given the small number of pa-
tients with mitral valve replacement that have participated
in this 6 year study we believe that no meaningful statistical
percentage can be calculated for this event and hence it has
been excluded from the event-free curve for mitral valve
replacement.
Table 4. Previous Major Cardiac Operative Procedures in 219 Patients
Operative Procedure AVR rvt VR TVR Multiple Overall
Coronary artery bypass grafting 2 I 2 5
Tricuspid annuloplasty 3 I 4
Mitral commissurotomy 3 17 2 4 26
Previous prosthetic valve 4 17 6 II 38
Other 2 5 3 10
Abbreviations as in Table 2.
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Table 5. Concomitant Major Cardiac Operative Procedures in 219 Patients
Operative Procedures
Coronary artery bypass grafting
LV aneurysm repair
Ascending aortic graft
Tricuspid anuloplasty
Mitral anuloplasty
Mitral commissurotomy
Enlargement of narrow aortic
root
Valve replacement other than
omniscience
Total
AVR
16
I
2
I
2
2
MVR
9
I
6
3
TVR
2
2
Multiple Overall
3 29
3
2
3 9
I
3
2
6
55
Abbreviations as in Table 2.
IV Unkno wn
Anticoagulant-induced hemorrhage (Fig. 7). This does
not include minor episodes such as epistaxis and cutaneou s
bleeding . A total of 14 patients had moderate to severe
hemorrhage , which was fatal in none (2.6% per patient-
year). The event-free curve in Figure 7 does not include
three patients who had early hemorrhage: one cardiac tam-
ponade 6 days postoperati vely, one intracerebral hemor-
rhage 5 days postoperatively and one hematoma at a pace-
maker site 12 days postoperatively . Although it is usual not
to include early postoperative bleeding episodes , all of these
patients were receiving warfarin and their prothrombin time
was above therapeutic range; therefore , it seems unfair to
us to exclude these patient s from the analysis.
Reoperation at site of valve prosthesis. Eight patients
underwent reoperation (1.5% per patient-year) for valvular
complications. The indications were endocarditis in three ,
periprosthetic leak in two, obstruction due to pannus for-
mation in one and valve thrombosis in two. Two patients
with endocarditis died after reoperation. Note must also be
made of two patients, one with valve thrombosis and one
with a periprosthetic leak , who died before they could re-
ceive corrective surgery.
Overall complications. Figure 8 shows an event-free
curve for freedom from all complications.
Figure 2. Patient improvement in terms of functional status (New
York Heart Association functional classification). a , preoperative;
b, postoperative.
AVR
Overall
MVR
16 MVR
11 AVR
31 Overall III
5
a b
4
35
25
69
3
44
31
88
Years
2
51
37
103
MVR 93 .3 :1:3 .7"
AVR 88 .2:1:5.1"
Overall 87 .9:1:3.1"
At Risk
96 74
67 54
194 103
o
90
100
Figure 1. Five year actuarial survival for patients at risk.
AVR = aortic valve replacement; MVR = mitral valve replace-
ment.
Pannus formation . Reoperation demonstrated that one
patient had valve dysfunction due to pannus formation (0.2%
per patient-year). This occurred about I year after mitral
valve replacement. At operation the Omniscience valve was
replaced with a tissue valve . Percent freedom from valve
obstruction due to pannus formation was 98.7% ± 1.3 for
mitral valve replacement , 100% for aortic valve replacement
and 99.4% ± 0 .6% overall.
Hemolysis. This was noted in one patient (0.2% per
patient-year), and was nonfatal. This patient showed evi-
dence of hemolysis 4 months after aortic valve replacement
and previously had the mitral valve replaced with another
mechanical prosthesis. She later developed a periprosthetic
leak. Freedom from hemolysis was 100% for mitral valve
replacement, 98.4% ± 1.6 for aortic valve replacement and
99 .5% ± 0.5 overall.
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Figure 4. Five year actuarial rates of freedom from periprosthetic
leak. Abbreviation as in Figure I .
Figure 3. Five year actuarial rates for freedom from endocarditis.
Abbreviation as in Figure I.
Discussion
Since the 1960s. prosthetic replacement of acquired and
congenital valvular lesions has been widely acce pted and
well establi shed . During the last two decades a wide variety
of prosthetic devices have been developed and continue to
Overall
54
~"VA
_--.. AVR
35 16 MVR
22 11 AVR
66 31 Overall
100~ •
E
0
"0
Q)
Q)
u:
~
MVR 96.71: 3.3%
AVR 90.91: 4.6%
Overall 95 .2:1: 2.3%
90
At Risk
90 74 5t 44
67 53 35 29
194 155 101 86
0 2 3
Years
Figure 5. Five year actuarial rates of freedom from thromboem-
bolic complications. Abbreviation as in Figure I.
be tested . The debate on the merits of mechanical versus
biologic prostheses continues and the assessment of the long-
term results of these valve replacements continues . The
major areas of concern regarding prosthetic valves are hemo-
dynamic performance , durability , thrombotic potential and
risk of bleeding due to anticoagulant therap y.
Operative mortality. Although there have been few
reports on the Omni science prosthesis , in vivo (4,5) and in
vitro (6) data ind icate excellent hem odynamic perform ance .
Operative mortal ity is more in keeping with the patient' s
preoperative status and other surgical factors than with valve-
related variables. In our series . no operative deaths were
due to valve-related complications. The significance of late
deaths is more complex especially when valve-related and
unrelated variables are includ ed as shown by our data on
surviva l based on the patient' s preoperative functional cla s-
sification and age.
Our series has a high percentage of patients coming for
reoperation (44 [20%] of 2 19) having valve malfunct ion of
complicated orig in such as endocarditis (20 [9. 1%] of 2 19)
and previous prosthet ic valve malfunction (22 [10%1 of
100%
96.2 ±2.6%
98.1 ±1 .1%
•
MVR
AVR
Overall
•••--.....-----4.---....--...--.... MVR
At Risk
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Table 6. Thromboembolic Complications in Patients at Risk
Throm boe mbolic No . of Linearized Rate No. of
Co mplicatio n Patients (% per patient-yr. ) Site Patients
TIA only II 2. 1 Visual symptoms 7
Vert igo/numbness 4
Embolism with recovery of 0 .2 Cerebra l I
de ficit
Embolism with residual 3 0 .6 Cerebral 2
defic it Retinal artery 2
Fatal 0 .2 I
TlA = transient ischemia attacks.
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Figure 8. Five year actuarial rates of freedom from all valve
related complications. Abbreviation as in Figure I.
However, we believe that our study of the complications in
these 194 patients compares favorably with the studies (7,9-
14) on patients with mechanical prostheses with respect to
thrombotic complications and anticoagulant-induced hem-
orrhage. Our results are well within the respectable range
(15). It has been well established that the risk of overall
thrombotic complications appears, on the whole, to be lin-
early related for up to 5 years. Limitation of disc movement
due to pannus formation can secondarily result in throm-
bosis, and we took particular care to ascertain the primary
event as either valve thrombosis or disc obstruction.
Thromboembolism is a linear related event and it is
probable that with additional follow-up more thromboem-
bolic events will occur. Most of the thromboembolic events
in our 6 year follow-up were of a minor nature (transient
ischemic attacks). The ratio of valve thrombosis to total
thromboembolic events was 15% (three valve thromboses
in a total of 20 thrombotic events), which again compares
well with data reported by others (16). We find that the
thrombogenic properties of this valve are well within the
accepted range. Although we have details of anticoagulant
therapy (drug used, patient compliance, therapy interrup-
tion, usual prothrombin time ratio) in most patients, because
of the small numbers involved we are unable to determine
statistically their influence on thrombotic complications.
However, it should be noted that one of our patients with
Ebstein's anomaly and repeat tricuspid valve replacement
for prosthetic valve thrombosis had a second thrombosis.
We believe that this was caused by an oversized prosthesis,
and since the insertion of a small prosthesis, she has been
asymptomatic for the last 18 months. On the other hand,
5
33
4
67
Overall 90.3 ± 2.6%
3
83
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Overall 98.7%0.9%
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194 149
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Figure 7. Five year actuarial ratesof freedom from anticoagulant-
induced hemorrhage.
Figure 6. Five year actuarial rates of freedom from valve throm-
bosis. Abbreviation as in Figure I.
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219). This may have been responsible for our somewhat
higher hospital mortality,
Late mortality. The overall actuarial survival in our
group at the end of 5 years was 87.9 ± 3. 1%; this compares
favorably with that reported by others. The number of late
deaths in the aortic valve replacement group are more than
in the mitral valve replacement group, possibly because of
the incidence of ischemic heart disease in the former. The
risk of endocarditis seemed to abate after the third year;
endocarditis was not seen in 86 patients at risk after the
third year. However, the mortality for reoperation for en-
docarditis remains high.
Complications (valve thrombosis and thromboem-
bolism). The difficulties regarding comparison among dif-
ferent reports on valvular prostheses are well described (7,8).
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there were two patients (one with tricuspid valve replace-
ment who had not taken warfarin after surgery for 22 months
and another who had aortic valve replacement who did not
take warfarin for 9 months after surgery) who had apparent
complications and remain well. The addition of dipyrida-
mole to warfarin may significantly reduce thrombotic com-
plications (17) in the future and we believe that this approach
should be explored.
Comparison with previous studies. Our results for
thrombotic complications are at marked variance with the
experience with this prosthesis reported by others (1,2).
Fananapazir et al. (2) observed thromboembolism in 14 of
96 patients (9.4% per patient-year), and Rabago et al. (1)
observed it in 6 of 146 patients (2.6% per patient-year).
Both series had a mean follow-up of only about 1.5 years
compared with our 2.8 years. Despite our longer follow-up
and larger number of patients our incidence of thromboem-
bolism was only 0.6% per patient-year; one after mitral,
one after tricuspid and one after triple valve replacement.
As pointed out before, we believe that the patient with
tricuspid valve replacement had an oversized prosthesis. We
consider, as do others (3,18,19), that technical factors re-
lating to the Omniscience prosthesis such as valve size,
orientation (20) and compromise of anticoagulation are ex-
tremely important. Biologic abnormalities from stagnation
(atrial fibrillation) and rheumatic etiology may have also
played a role in the previous poor results with this valve
(1,2).
Other complications. Our results for periprosthetic
leakage (0.6% per patient-year) also contrast sharply with
those of Fananapazir and Rabago and co-workers (1,2).
Here again the roles of technical factors (21,22) and of
nontechnical factors like endocarditis and myxoid degen-
eration have clearly been established. When the broad
definition of "valve failure" is used (any complication re-
sulting in death or reoperation including that for anticoag-
ulant-induced hemorrhage), then a total of 18 patients can
be classified in this group (endocarditis 4, pannus/tissue
obstruction 1, valve thrombosis 3, thromboembolism 1,
periprosthetic leak 3, and anticoagulant hemorrhage 7. This
gives an annual rate of 3.4 per patient-year. We have further
studies in progress on this prosthesis and preliminary data
suggest that the results are even better.
Conclusions. The incidence of complications in our se-
ries equals or betters those previously reported (7). Hem-
orrhagic complications caused by anticoagulant agents seem
to be to some extent unavoidable. On the other hand, the
durability of the Omniscience valve has been unmarred by
disruption or by structural failure. The quality of life after
surgery has been satisfactory as shown by the marked im-
provement in functional status. Our data indicate that the
Omniscience valve is safe, has a low incidence of compli-
cations and provides excellent performance.
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